Healthcare private equity firms Hildred Capital Management, (Hildred) and Bourne Partners Strategic Capital (Bourne), together with The Emerson Group (Emerson), have launched Carlin Consumer Health (Carlin) to establish a preeminent consumer health business and to acquire leading over-the-counter (OTC) brands.
Healthcare private equity firms Hildred Capital Management, (Hildred) and Bourne Partners Strategic Capital (Bourne), together with The Emerson Group (Emerson), have launched Carlin Consumer Health (Carlin) to establish a preeminent consumer health business and to acquire leading over-the-counter (OTC) brands.
Carlin will acquire and commercialise well-established brands as well as support its retail partners and their customers.
In connection with its formation, Carlin today has acquired Zegerid OTC (Zegerid) from Bayer AG (Bayer). Zegerid is an OTC proton pump inhibitor used for the treatment of frequent heartburn.
Carlin represents Hildred’s third platform investment in the OTC industry, and the Zegerid acquisition emerged from Bourne’s partnership with Emerson. The financial terms have not been disclosed.
